We observed that iPA treatment of GBM cells inhibited the phosphorylation of IKKβ, IκBα and NF‐κB, thus preventing the NF‐κB interaction with PKM promoter causing the reduction of PKM2 expression and proteins levels (Figs 5 and 6). The gene discussed is NFKB1; the disease is glioblastoma.